Clinical Testing of the First Suspension BHK-M Cell Platform Derived Biotherapeutic

第一个悬浮 BHK-M 细胞平台衍生的生物治疗药物的临床测试

• 批准号: 9759962
• 负责人: Gabriela Denning
• 金额: $ 75.21万
• 依托单位: EXPRESSION THERAPEUTICS
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-08-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9759962
• 关键词: Antibodies; Biological Response Modifier Therapy; Biological Sciences; Biomanufacturing; Biomedical Engineering; Bioreactors; Blood Coagulation Factor; Businesses; Canada; Capital; Caring; Cell Line; Cells; Chemistry; Clinical; Complication; Consumption; Contracts; Country; Data Analyses; Development; Development Plans; Documentation; Dose; Economics; F8 gene; Factor VIII; Family suidae; Feedback; Goals; Half-Life; Hamsters; Hemophilia A; Hemorrhage; Human; Immune Tolerance; Infusion procedures; Insurance; International; Investments; Iowa; Kidney; Label; Laboratories; Legal patent; M cell; Materials Testing; Methods; Multicenter Trials; National Heart, Lung, and Blood Institute; Neoadjuvant Therapy; Patients; Persons; Pharmaceutical Preparations; Pharmacology and Toxicology; Phase; Policies; Population; Prevention; Process; Production; Productivity; Proteins; Protocols documentation; R-factor; Recombinants; Records; Recovery; Reporting; Research; Resources; Running; Safety; Serum; Services; Small Business Innovation Research Grant; Suspensions; System; Technology; Technology Transfer; Teenagers; Testing; Therapeutic; Treatment Efficacy; Treatment Factor; Western Europe; Work; barrier to care; cell bank; clinical development; clinical material; commercialization; cost; design; first-in-human; improved; inhibitor/antagonist; innovation; meetings; novel; off-patent; open label; preclinical development; primary endpoint; programs; recombinant antihemophilic factor VIII; research clinical testing; safety study; stability testing; therapy design

PROJECT SUMMARY/ABSTRACT The long-term objective of current project is to commercialize a novel coagulation factor product manufactured using a novel production cell line, designated ET3i/BHK-M with a primary indication of treatment of anti-drug antibodies that develop following the treatment of congenital hemophilia A with factor VIII (fVIII) replacement products. Expression Therapeutics has developed multiple technologies that, when integrated, provide a highly efficient biomanufacturing platform designed for improved volumetric productivity. In the phase I SBIR project periods, Expression Therapeutics generated and validated a research cell bank demonstrating the highest levels of recombinant factor VIII reported to date, completed upstream and downstream process development, and successfully transferred the technology to a contract manufacturing organization for production of phase I clinical test material. The current application seeks to complete all manufacturing, nonclinical, clinical planning, and regulatory activities required to conduct a phase I first-in-man trial of ET3i/BHK-M, with the primary endpoint of safety and tolerability.

项目总结/摘要 本项目的长期目标是将生产的新型凝血因子产品商业化。 使用命名为ET 3 i/BHK-M的新生产细胞系，其主要适应症为抗药物治疗， 用因子VIII（fVIII）替代治疗先天性血友病A后产生的抗体 产品. Expression Therapeutics开发了多种技术，当这些技术整合在一起时， 高效的生物制造平台，旨在提高体积生产率。在SBIR项目第一阶段， 期间，Expression Therapeutics生成并验证了一个研究细胞库，该细胞库显示出最高水平 已完成上游和下游工艺开发，以及 成功地将该技术转让给合同生产组织，用于生产I期临床 试验材料。当前应用程序旨在完成所有制造、非临床、临床计划和 进行ET 3 i/BHK-M I期首次人体试验所需的监管活动，主要终点为 安全性和耐受性。